Investment Rating - The report maintains a "Buy" rating for Shanghai Jahwa [4] Core Insights - The company's 2025 performance met expectations, with a significant recovery in operational quality, achieving a revenue of 6.317 billion yuan, a year-on-year increase of 11.25%, and a net profit of 268 million yuan, successfully turning a profit [1] - The gross margin improved to 62.6%, up by 5.0 percentage points year-on-year, indicating enhanced profitability [1] - The company aims for double-digit revenue growth in 2026, focusing on high-potential segments and expanding its portfolio of billion-yuan products [2][4] Financial Performance - In 2025, the personal care segment generated 2.419 billion yuan, a growth of 1.65%, while the beauty segment saw a remarkable increase of 53.70%, reaching 1.613 billion yuan [2] - The overseas business reported a revenue of 1.471 billion yuan, up by 3.9% [2] - The company’s online sales grew by 21.89%, with an improved gross margin of 3.28 percentage points year-on-year, while offline sales increased by 4.60% with a gross margin rise of 5.75 percentage points [3] Profit Forecast - The profit forecast for 2026-2028 has been adjusted, with expected net profits of 422 million yuan, 529 million yuan, and 649 million yuan respectively, translating to EPS of 0.63, 0.79, and 0.96 yuan per share [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [4]. Core Insights - The company reported a revenue of 5.051 billion yuan for 2025, representing a year-on-year growth of 30%, with a net profit attributable to the parent company of 1.204 billion yuan, up 36.73% year-on-year [1]. - The company's gross margin for 2025 was 84.22%, a slight decrease of 0.15 percentage points, while the net margin improved by 1.18 percentage points to 23.87% [1]. - The company has seen significant growth in both offline and online sales channels, with offline sales reaching 2.426 billion yuan (up 24.49% year-on-year) and online sales at 2.477 billion yuan (up 38.83% year-on-year) [3]. Revenue and Profitability - In 2025, the cosmetics segment generated 2.996 billion yuan in revenue, a growth of 30.04%, while the skincare segment achieved 1.873 billion yuan, growing by 31.08% [2]. - The average selling price for cosmetics was 176.4 yuan, and for skincare, it was 328.3 yuan, showing slight changes from the previous year [2]. - The company expects net profits to reach 1.583 billion yuan in 2026, 2.041 billion yuan in 2027, and 2.583 billion yuan in 2028, with corresponding P/E ratios of 20, 16, and 12 times [4][6]. Market Expansion - The company has expanded its offline presence with 412 self-operated counters and 33 distributor counters, marking an increase in average revenue per comparable self-operated counter to 5.6 million yuan [3]. - The company opened its first overseas self-operated counter in Hong Kong, indicating ongoing globalization efforts [3]. - The overall repurchase rate for the company's membership system reached 33.3%, an increase of 2.4 percentage points year-on-year [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [3]. Core Insights - The company reported a strong performance for the year ending December 31, 2025, with total revenue of 9.18 billion yuan, a year-on-year increase of 35.1%, and a net profit of 1.15 billion yuan, up 43.7% year-on-year. The gross margin improved from 75.2% in 2024 to 76.4% in 2025, driven by an increase in the proportion of online self-operated channels and mid-to-high-end brands [1]. - The company declared a final dividend of 0.75 yuan per share for the fiscal year 2025, resulting in a total dividend payout of 498 million yuan [1]. - The brand "韩束" achieved revenue of 7.36 billion yuan in 2025, reflecting a growth of 31.6%, with significant contributions from various product lines and a user base exceeding 100 million [2]. - The "Newpage" brand saw remarkable growth, with revenue reaching 880 million yuan, a staggering increase of 134.2% [2]. - The company anticipates net profits for 2026, 2027, and 2028 to be 1.375 billion yuan, 1.681 billion yuan, and 1.941 billion yuan, respectively, with corresponding price-to-earnings ratios of 14, 12, and 10 times [3]. Financial Summary - For the fiscal year 2025, the company achieved a revenue of 9.18 billion yuan, with a year-on-year growth rate of 35.1% [5]. - The projected revenues for the years 2026 to 2028 are 11.49 billion yuan, 13.91 billion yuan, and 16.05 billion yuan, respectively, with corresponding growth rates of 25.22%, 21.06%, and 15.39% [5]. - The net profit for 2025 was 1.10 billion yuan, with a year-on-year increase of 41.14%, and is expected to grow to 1.37 billion yuan in 2026 [5].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [4][7]. Core Insights - The company reported impressive growth in 2025, achieving sales of 31.4 billion yuan, a year-on-year increase of 220.3%. Revenue reached 27.3 billion yuan, also up by 221.0%. Gross profit was 10.3 billion yuan, reflecting a 193.4% increase, although the gross margin decreased to 37.6% due to rising gold prices following price adjustments [2][4]. - The net profit for the year was 4.9 billion yuan, a significant increase of 230.5%, with adjusted net profit at 5.0 billion yuan, up 234.9% [2]. - For Q1 2026, the company anticipates sales performance (including tax revenue) between 19.0 to 20.0 billion yuan, with revenue expected to be around 16.5 to 17.5 billion yuan and net profit projected at approximately 3.6 to 3.8 billion yuan [2]. Financial Performance Summary - The company achieved a total revenue of 27.3 billion yuan in 2025, with a gross profit margin of 37.6%. The net profit was reported at 4.9 billion yuan [2][4]. - The company’s inventory reached 16.0 billion yuan, with cash and bank balances of 2.1 billion yuan by the end of 2025 [2]. - The company’s financial projections for 2026 to 2028 estimate net profits of 8.48 billion yuan, 11.11 billion yuan, and 13.49 billion yuan respectively, with corresponding P/E ratios of 13, 10, and 8 times [4][6]. Market Expansion and Brand Strength - The company has successfully expanded its physical presence, with 45 self-operated stores by the end of 2025, including 10 new stores opened during the year. The same-store sales growth was impressive at 160.6% [3]. - The company opened its first overseas store in Singapore, marking a significant milestone in its international expansion [3]. - Online sales surged to 4.7 billion yuan, a remarkable growth of 341.3%, increasing its share of total revenue to 17.1% [3]. - The loyalty program saw membership grow to approximately 610,000, a year-on-year increase of 74.3%, indicating a growing consumer base [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market benchmark [4][7]. Core Insights - The company achieved impressive sales growth of 31.4 billion yuan in 2025, representing a year-on-year increase of 220.3%. Revenue reached 27.3 billion yuan, also up 221.0%. Gross profit was 10.3 billion yuan, with a growth of 193.4%, although the gross margin decreased to 37.6% due to rising gold prices following two price adjustments in 2025 [2][4]. - The net profit for the year was 4.9 billion yuan, marking a 230.5% increase, while adjusted net profit reached 5.0 billion yuan, up 234.9% [2]. - For Q1 2026, the company expects sales performance (including tax revenue) to be between 19.0 to 20.0 billion yuan, with revenue around 16.5 to 17.5 billion yuan and net profit estimated at 3.6 to 3.8 billion yuan [2]. Sales Channels and Growth - The company reported significant growth in its offline channels, with store revenue reaching 22.6 billion yuan, a year-on-year increase of 204.0%, accounting for 82.9% of total revenue. Same-store sales grew by 160.6% [3]. - As of the end of 2025, the company had opened 45 self-operated stores, adding 10 new stores during the year and optimizing 9 existing stores in commercial centers [3]. - The company opened its first overseas store in Singapore's Marina Bay Sands on June 21, 2025, marking a significant milestone in its international expansion [3]. - Online sales surged to 4.7 billion yuan, a remarkable growth of 341.3%, increasing its share of total revenue to 17.1% [3]. - The loyalty program saw membership grow to approximately 610,000, a 74.3% increase year-on-year, indicating a growing consumer base [3]. Financial Forecast - The company is projected to achieve net profits of 8.48 billion yuan, 11.11 billion yuan, and 13.49 billion yuan for the years 2026, 2027, and 2028, respectively, with corresponding price-to-earnings (P/E) ratios of 13x, 10x, and 8x [4][6]. - Revenue forecasts for the upcoming years are as follows: 43.54 billion yuan in 2026, 56.98 billion yuan in 2027, and 69.23 billion yuan in 2028, with year-on-year growth rates of 59.45%, 30.89%, and 21.50% respectively [6][8].

Investment Rating - The report assigns a "Buy" rating to the company with a current price of 29.82 HKD and a fair value of 39.24 HKD [4]. Core Insights - The company, Leshu, is a leading player in the sanitary products market in emerging markets, particularly in Africa, with significant market shares of 20% in baby diapers and 16% in sanitary napkins as of 2024 [8]. - The company has established a strong operational presence with eight factories and 18 sales branches across over 30 countries, indicating robust market penetration [8]. - The African sanitary products industry is expected to grow steadily, driven by population growth and economic development, with a compound annual growth rate (CAGR) of 6.8% from 2020 to 2024 [8]. - Leshu has built high barriers to entry through local production and channel management, positioning itself as a leader in the market [8]. - Future growth prospects include expanding into Latin America and diversifying product lines into daily consumer goods [8]. Financial Summary - Revenue projections for 2024 to 2028 show a steady increase from 454 million USD in 2024 to 875 million USD in 2028, with growth rates of 10.5%, 24.9%, 15.9%, 15.5%, and 15.2% respectively [2]. - Non-GAAP net profit is expected to rise from 98 million USD in 2024 to 186 million USD in 2028, reflecting growth rates of 24.4%, 15.3%, 14.2%, and 15.5% [2]. - The company's Non-GAAP EPS is projected to increase from 0.20 HKD in 2025 to 0.30 HKD in 2028, with a corresponding decrease in Non-GAAP PE from 20.9 to 12.7 [2]. - The expected Non-GAAP ROE is forecasted to remain strong, starting at 70.3% in 2024 and stabilizing around 20% by 2028 [2]. Market Position and Strategy - Leshu's strategy includes deepening market coverage through a robust distribution network, with plans to strengthen its presence in existing markets while exploring new regions [8]. - The company aims to leverage its local manufacturing capabilities to enhance product affordability and quality, thereby maintaining a competitive edge [8]. - The management team, with extensive experience in the fast-moving consumer goods sector, is focused on sustainable growth and operational efficiency [19].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company, 巨子生物 (2367.HK), reported a slight decline in revenue and profit for the year ending December 31, 2025, with total revenue of 55.19 billion yuan, down 0.37% year-on-year, and a net profit of 19.15 billion yuan, down 7.15% year-on-year [1]. - The company's gross margin was 80.34%, a decrease of 1.76 percentage points compared to the previous year, while the net profit margin fell to 34.70%, down 2.54 percentage points year-on-year [1]. - The second half of 2025 saw a significant impact from public sentiment issues, leading to a revenue drop of 19.76% and a net profit decline of 32.10% [1]. - The company is recognized as a leading player in the global recombinant collagen market, focusing on research and development to expand its eight consumer brands [4]. Financial Performance Summary - For 2025, the company achieved a revenue of 55.19 billion yuan, with a year-on-year decrease of 0.37%, and a net profit of 19.15 billion yuan, reflecting a 7.15% decline [1][6]. - The company forecasts net profits for 2026, 2027, and 2028 to be 19.49 billion yuan, 21.34 billion yuan, and 23.45 billion yuan, respectively, with corresponding price-to-earnings ratios of 15, 14, and 12 times [4][6]. - The revenue is expected to grow to 61.17 billion yuan in 2026, representing a year-on-year increase of 10.85% [6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company, 巨子生物 (2367.HK), reported a slight decline in revenue and profit for the year ending December 31, 2025, with total revenue of 55.19 billion yuan, down 0.37% year-on-year, and a net profit of 19.15 billion yuan, down 7.15% year-on-year [1]. - The company's gross margin was 80.34%, a decrease of 1.76 percentage points compared to the previous year, while the net profit margin fell to 34.70%, down 2.54 percentage points year-on-year [1]. - In the second half of 2025, the company faced significant challenges due to public sentiment issues, leading to a 19.76% decline in revenue to 24.05 billion yuan and a 32.10% drop in net profit to 7.32 billion yuan [1]. - The company is recognized as a leading player in the global recombinant collagen market and is expanding its product portfolio across eight consumer brands [4]. Financial Performance Summary - For 2025, the company achieved a revenue of 55.19 billion yuan, with a year-on-year decline of 0.37%, and a net profit of 19.15 billion yuan, down 7.15% [1][6]. - The company forecasts net profits for 2026, 2027, and 2028 to be 19.49 billion yuan, 21.34 billion yuan, and 23.45 billion yuan respectively, with corresponding price-to-earnings ratios of 15, 14, and 12 [4][6]. - The revenue for 2026 is projected to increase to 61.17 billion yuan, reflecting a growth rate of 10.85% [6]. Brand Performance - The 可复美 brand generated revenue of 44.70 billion yuan in 2025, a slight decline of 1.58%, while the 可丽金 brand saw a revenue increase of 9.21% to 9.18 billion yuan [2]. - The company plans to launch significant new products in 2026, including an upgraded collagen stick and a new collagen repair series [2][3]. - Direct-to-consumer (DTC) sales through online channels accounted for 34.02 billion yuan, down 5.16%, while online sales through e-commerce platforms increased by 34.84% to 5.09 billion yuan [2].

Core Viewpoint - On December 2, a total of 8 stocks received buy ratings from brokerages, with BYD having the highest target price indicating a potential increase of 44.9% [1] Group 1: Stock Ratings - 5 stocks maintained their ratings, while 3 stocks received their ratings for the first time [1] - The semiconductor and semiconductor equipment sector had the highest number of stocks with buy ratings, totaling 2 stocks [1] - The household and personal products sector, as well as the food, beverage, and tobacco sector, each had 1 stock with a buy rating [1]

Investment Rating - The report maintains a "Buy" rating for Shanghai Jahwa, indicating an expected stock price increase exceeding 15% compared to the benchmark index [3][10]. Core Insights - Shanghai Jahwa reported a revenue of 4.961 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 10.83%. The net profit attributable to the parent company reached 405 million yuan, up 149.12% year-on-year, with a non-recurring net profit of 231 million yuan, increasing by 92.35% [1][2]. - The gross margin for the first three quarters was 62.81%, an increase of 3.39 percentage points year-on-year, while the net profit margin was 8.17%, up 4.54 percentage points year-on-year [1]. - In Q3 2025, the company achieved a revenue of 1.483 billion yuan, a significant year-on-year increase of 28.29%, and a net profit of 140 million yuan, soaring by 285.35% year-on-year [1][2]. Revenue Breakdown - For the first three quarters of 2025, the personal care segment generated 2.196 billion yuan, a slight increase of 3.55% year-on-year. The cosmetics segment saw revenue of 1.101 billion yuan, a growth of 66.6%. However, overseas business revenue declined by 1.97% to 1.067 billion yuan, and innovative business revenue fell by 0.58% to 595 million yuan [2]. - In Q3 2025, the personal care and cosmetics segments reported revenues of 606 million yuan and 354 million yuan, respectively, with year-on-year growth of 14% and 272% [2]. Strategic Initiatives - The company is focusing on product innovation, marketing upgrades, and channel optimization. Key products include the portable mosquito repellent egg, Yuze dry-sensitive cream, and Baicaoji white mud mask, all of which have achieved significant sales milestones [2]. - The online channel revenue for domestic business grew by 170% year-on-year in Q3, marking the first time that online revenue contribution exceeded 50% of total domestic revenue [2]. Financial Forecast - The report adjusts the profit forecast for Shanghai Jahwa, projecting net profits of 400 million yuan, 488 million yuan, and 582 million yuan for 2025, 2026, and 2027, respectively. The expected earnings per share (EPS) are 0.60 yuan, 0.73 yuan, and 0.87 yuan, corresponding to price-to-earnings (P/E) ratios of 42x, 34x, and 29x [3][5].